121 related articles for article (PubMed ID: 1717841)
21. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
Akerblom L; Nara P; Dunlop N; Putney S; Morein B
Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
[TBL] [Abstract][Full Text] [Related]
22. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
Boudet F; Girard M; Theze J; Zouali M
Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.
Kim YB; Han DP; Cao C; Cho MW
Virology; 2003 Jan; 305(1):124-37. PubMed ID: 12504547
[TBL] [Abstract][Full Text] [Related]
24. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
26. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
[TBL] [Abstract][Full Text] [Related]
27. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.
Zheng NN; McElrath MJ; Sow PS; Hawes SE; Diallo-Agne H; Stern JE; Li F; Mesher AL; Robinson AD; Gottlieb GS; Huang Y; Kiviat NB
J Virol; 2007 Sep; 81(17):9061-71. PubMed ID: 17582003
[TBL] [Abstract][Full Text] [Related]
28. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
[TBL] [Abstract][Full Text] [Related]
29. An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais.
Bond KB; Sriwanthana B; Hodge TW; De Groot AS; Mastro TD; Young NL; Promadej N; Altman JD; Limpakarnjanarat K; McNicholl JM
AIDS Res Hum Retroviruses; 2001 May; 17(8):703-17. PubMed ID: 11429111
[TBL] [Abstract][Full Text] [Related]
30. Covariability of selected amino acid positions for HIV type 1 subtypes C and B.
Gilbert PB; Novitsky V; Essex M
AIDS Res Hum Retroviruses; 2005 Dec; 21(12):1016-30. PubMed ID: 16379605
[TBL] [Abstract][Full Text] [Related]
31. Epitope mapping of murine monoclonal antibodies against human immunodeficiency virus type 1 Nef.
Otake K; Fujii Y; Tashiro M; Adachi A; Kitoh J
Exp Anim; 1997 Jan; 46(1):53-8. PubMed ID: 9027472
[TBL] [Abstract][Full Text] [Related]
32. Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection.
Malhotra U; Li F; Nolin J; Allison M; Zhao H; Mullins JI; Self S; McElrath MJ
J Virol; 2007 May; 81(10):5225-37. PubMed ID: 17329342
[TBL] [Abstract][Full Text] [Related]
33. Identification and characterization of HLA-A*3303-restricted, HIV type 1 Pol- and Gag-derived cytotoxic T cell epitopes.
Hossain MS; Tomiyama H; Inagawa T; Ida S; Oka S; Takiguchi M
AIDS Res Hum Retroviruses; 2003 Jun; 19(6):503-10. PubMed ID: 12882660
[TBL] [Abstract][Full Text] [Related]
34. Common antibody dependent cell mediated cytotoxicity (ADCC) antibody epitopes of HIV-1 CRF01_AE Env and Gag in early HIV-1 infected individuals.
Sangjan S; Ampol S; Tabprasit S; Horthongkham N; Chuenchitra T; Ekpo P; Kantakamalakul W
Asian Pac J Allergy Immunol; 2019 Mar; 37(1):43-50. PubMed ID: 29602284
[TBL] [Abstract][Full Text] [Related]
35. Fine mapping of HIV-1 Nef-epitopes by monoclonal antibodies.
Siakkou H; Jahn S; Kienzle N; Ulrich R; Grötzinger C; Schneider T; Kohleisen B; Pauli G; Spohn R; Jung G
Arch Virol; 1993; 128(1-2):81-95. PubMed ID: 7678193
[TBL] [Abstract][Full Text] [Related]
36. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
[TBL] [Abstract][Full Text] [Related]
37. CTL response to HIV type 1 subtype C is poorly predicted by known epitope motifs.
Ngandu NG; Bredell H; Gray CM; Williamson C; Seoighe C;
AIDS Res Hum Retroviruses; 2007 Aug; 23(8):1033-41. PubMed ID: 17725421
[TBL] [Abstract][Full Text] [Related]
38. [Specific immune responses to human immunodeficiency virus type 1 Gag, Tat, Rev and Nef proteins].
Zhai S; Kang WZ; Yu X; Wang SY; Walker BD; Altfeld M; Sun YT
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):175-9. PubMed ID: 15766402
[TBL] [Abstract][Full Text] [Related]
39. Prediction of HIV peptide epitopes by a novel algorithm.
Roberts CG; Meister GE; Jesdale BM; Lieberman J; Berzofsky JA; De Groot AS
AIDS Res Hum Retroviruses; 1996 May; 12(7):593-610. PubMed ID: 8743085
[TBL] [Abstract][Full Text] [Related]
40. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
